Fujirebio Europe Expands Its Portfolio With Introduction of the Innovative PreCursor-M AnoGYN assay (RUO) for Methylation Testing in Anal Specimens

Contributed by: Business Wire

Logo

Tags

Oncology

Medical Supplies

Health

Medical Devices

Research

Science

Biotechnology

FUJIREBIO

More Like This

PR Newswire associated0

Roche receives CE Mark for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for ELAHERE

Fujirebio Launches the Fully Automated Lumipulse® G GFAP Assay for Research Use Only and Further Strengthens its Neuro Test Menu

PR Newswire associated0

Seegene Showcases HPV Diagnostic Kits and PCR Technology at AOGIN 2024

BioGX Candida Auris PCR Assay Global Adoption Accelerates

PR Newswire associated0

AI Diagnostic Platform Company Noul Enters Cancer Diagnostic Business with the Launch of Cervical Cell Analysis Product

PR Newswire associated0

/C O R R E C T I O N -- Menarini Silicon Biosystems/

PR Newswire associated0

A. Menarini Diagnostics and Nucleix announce a strategic partnership for a non-invasive bladder cancer test in Europe

Beckman Coulter and Fujirebio Expand Partnership to Develop Patient-friendly, Blood-based Neurodegenerative Disease Diagnostics